Oral connexin43–peptide–loaded milk extracellular vesicles mitigate lethal radiation injury while preserving tumour radiosensitivity
Cancer Letters · 2026-09 · 656 · 218686
DOI: 10.1016/j.canlet.2026.218686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-09. Verfasst von Spencer R Marsh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vascular and Heart Research, Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, VA, 24016, USA. Electronic address: …. Hauptthemen laut MEDLINE: Connexin 43, Radiation Tolerance, Extracellular Vesicles, Glioma. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Ionizing radiation is central to cancer therapy, where normal-tissue toxicity limits dose escalation, and is also a major hazard in accidental or mass-casualty exposures, where practical radiomitigators for radiosensitive organs are urgently needed. We investigated orally delivered milk extracellular vesicles (mEVs) loaded with the connexin43 carboxyl-terminal peptide αCT11 (XOlacta) in a murine 14 Gy total-body irradiation model and a syngeneic GL261 glioma radiotherapy model. A single oral XOlacta dose given 1 h after total-body irradiation conferred 42% 30-day survival despite an expected 100% lethality from a 14 Gy challenge, with marked preservation of ileal architecture and femoral bone marrow cellularity, and significant benefit was retained when dosing was delayed to 24 h. Biodistribution studies with fluorescently labeled mEVs showed radiation-enhanced uptake in brain, gut, and bone marrow, consistent with injury-licensed targeting of radiosensitive tissues. In glioma-bearing mice, XOlacta protected normal tissues without diminishing tumour radiosensitivity. These findings identify oral αCT11-loaded mEVs as a potent, non-parenteral radiomitigator that preserves normal-tissue integrity while maintaining tumour response in a therapeutic context, and support connexin-linked mEV-targeting as a promising strategy for both radiotherapy adjuncts and management of high-dose radiation exposures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Vascular and Heart Research, Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, VA, 24016, USA. Electronic address: srmarsh@vtc.vt.edu.
- Center for Vascular and Heart Research, Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, VA, 24016, USA.
- Cancer Research Center, Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, VA, 24016, USA.
- Department of Chemical Engineering, University of Virginia, Charlottesville, VA, 22903, USA.
- Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Roanoke, VA, 24016, USA.
- Center for Vascular and Heart Research, Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, VA, 24016, USA; Cancer Research Center, Fralin Biomedical Research Institute at Virginia Tech Carilion, Ro…
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Marsh, S. R., Beard, C., Sheng, Z., Bannon, M. S., Amin, M. R., Letteri, R. A., Athanasiadi, I., & Gourdie, R. G. (2026). Oral connexin43–peptide–loaded milk extracellular vesicles mitigate lethal radiation injury while preserving tumour radiosensitivity. Cancer Letters, 656, 218686. https://doi.org/10.1016/j.canlet.2026.218686
Vancouver
Marsh SR, Beard C, Sheng Z, Bannon MS, Amin MR, Letteri RA, et al. Oral connexin43–peptide–loaded milk extracellular vesicles mitigate lethal radiation injury while preserving tumour radiosensitivity. Cancer Letters. 2026;656:218686. doi:10.1016/j.canlet.2026.218686
BibTeX
@article{Marsh2026,
author = {Marsh, Spencer R and Beard, Claire and Sheng, Zhi and Bannon, Mark S and Amin, Md Ruhul and Letteri, Rachel A and Athanasiadi, Ilektra and Gourdie, Robert G},
title = {Oral connexin43–peptide–loaded milk extracellular vesicles mitigate lethal radiation injury while preserving tumour radiosensitivity},
journal = {Cancer Letters},
year = {2026},
volume = {656},
pages = {218686},
doi = {10.1016/j.canlet.2026.218686}
}
EUVIMED